The stock of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) last traded at $3.14, down -1.26% from the previous session.
ZNTL stock price is now -5.42% away from the 50-day moving average and -52.41% away from the 200-day moving average. The market capitalization of the company currently stands at $229.47M.
With the price target maintained at $4, Wedbush recently Upgraded its rating from Underperform to Neutral for Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL). On June 20, 2024, UBS Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $28 to quote $5, while ‘Wells Fargo’ rates the stock as ‘Equal Weight’
In other news, Diana Hausman, Former Chief Medical Officer bought 9,888 shares of the company’s stock on Oct 31 ’24. The stock was bought for $28,294 at an average price of $2.86. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 04 ’24, Principal Accounting Officer Vultaggio Vincent sold 1,603 shares of the business’s stock. A total of $5,098 was realized by selling the stock at an average price of $3.18. This leaves the insider owning 33,855 shares of the company worth $0.11 million. A total of 19.17% of the company’s stock is owned by insiders.
During the past 12 months, Zentalis Pharmaceuticals Inc has had a low of $2.66 and a high of $18.07. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 7.29, and a quick ratio of 7.29. The fifty day moving average price for ZNTL is $3.3147 and a two-hundred day moving average price translates $6.65225 for the stock.
The latest earnings results from Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was released for 2024-09-30. The net profit margin was -442.02% and return on equity was -42.89% for ZNTL.
